Skip to main content
Top
Published in: Supportive Care in Cancer 11/2016

Open Access 01-11-2016 | Original Article

Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment

Authors: Noah R. Zanville, Kelly N. H. Nudelman, Dori J. Smith, Diane Von Ah, Brenna C. McDonald, Victoria L. Champion, Andrew J. Saykin

Published in: Supportive Care in Cancer | Issue 11/2016

Login to get access

Abstract

Purpose

To describe the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on breast cancer survivors’ (BCS) perceived ability to work post-treatment.

Methods

The sample included 22 chemotherapy-treated (Ctx+) and 22 chemotherapy-naïve (Ctx−) female BCS. Data was collected at the following three time points: baseline (post-surgery, pre-chemotherapy), 1 month (1 M) post-chemotherapy, and approximately 1 year (1 Y) later. The presence, frequency, number, and severity of CIPN-sx were self-reported using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity questionnaire (FACT/GOG-Ntx) version 4, a validated 11-item CIPN measure. Perceived ability to work was measured using an item from the Functional Well-Being subscale of the FACT/GOG-Ntx.

Results

At 1 Y, more than 50 % of Ctx+ reported discomfort, numbness, or tingling in their hands or feet; weakness; or difficulty feeling small objects. The presence, number, and severity of these symptoms were correlated with being less able to work for Ctx+ at 1 M but not 1 Y. Results of a regression analysis using CIPN-sx to predict work ability found that models combining (1) hand numbness and trouble feeling small objects, (2) trouble buttoning buttons and trouble feeling small objects, (3) foot numbness and foot pain, (4) foot numbness and trouble walking, and (5) trouble hearing and hand pain each predicted survivors who were “not at all” able to work at 1 M.

Conclusions

Unresolved CIPN-sx may play a role in challenges working for BCS post-treatment. These findings highlight the need for research to explore the impact that CIPN-sx have on BCS’ ability to work, as well as the development of interventions to improve work function in BCS with CIPN-sx.
Literature
1.
2.
go back to reference Spelten ER, Sprangers MA, Verbeek JH (2002) Factors reported to influence the return to work of cancer survivors: a literature review. Psychooncology 11(2):124–131CrossRefPubMed Spelten ER, Sprangers MA, Verbeek JH (2002) Factors reported to influence the return to work of cancer survivors: a literature review. Psychooncology 11(2):124–131CrossRefPubMed
3.
go back to reference Tamminga SJ et al. (2012) Breast cancer survivors’ views of factors that influence the return-to-work process—a qualitative study. Scand J Work Environ Health 38(2):144–154CrossRefPubMed Tamminga SJ et al. (2012) Breast cancer survivors’ views of factors that influence the return-to-work process—a qualitative study. Scand J Work Environ Health 38(2):144–154CrossRefPubMed
4.
go back to reference Ahn E et al. (2009) Impact of breast cancer diagnosis and treatment on work-related life and factors affecting them. Breast Cancer Res Treat 116(3):609–616CrossRefPubMed Ahn E et al. (2009) Impact of breast cancer diagnosis and treatment on work-related life and factors affecting them. Breast Cancer Res Treat 116(3):609–616CrossRefPubMed
5.
go back to reference Banning M (2011) Employment and breast cancer: a meta-ethnography. Eur J Cancer Care (Engl) 20(6):708–719CrossRef Banning M (2011) Employment and breast cancer: a meta-ethnography. Eur J Cancer Care (Engl) 20(6):708–719CrossRef
6.
go back to reference Bradley CJ et al. (2005) Short-term effects of breast cancer on labor market attachment: results from a longitudinal study. J Health Econ 24(1):137–160CrossRefPubMed Bradley CJ et al. (2005) Short-term effects of breast cancer on labor market attachment: results from a longitudinal study. J Health Econ 24(1):137–160CrossRefPubMed
7.
go back to reference Mahon, S.M., et al. (2011) Breast cancer, in Site specific series, S.M. Mohan, Editor. Oncology Nursing Society. 248 Mahon, S.M., et al. (2011) Breast cancer, in Site specific series, S.M. Mohan, Editor. Oncology Nursing Society. 248
8.
go back to reference de Boer, A.G., et al. (2011) Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev (2): p. CD007569 de Boer, A.G., et al. (2011) Interventions to enhance return-to-work for cancer patients. Cochrane Database Syst Rev (2): p. CD007569
9.
go back to reference Wolf SL et al. (2012) The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20(3):625–632CrossRefPubMed Wolf SL et al. (2012) The relationship between numbness, tingling, and shooting/burning pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) as measured by the EORTC QLQ-CIPN20 instrument, N06CA. Support Care Cancer 20(3):625–632CrossRefPubMed
10.
go back to reference Hershman DL et al. (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967CrossRefPubMed Hershman DL et al. (2014) Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32(18):1941–1967CrossRefPubMed
11.
go back to reference Mols, F., et al. (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer Mols, F., et al. (2014) Chemotherapy-induced peripheral neuropathy and its association with quality of life: a systematic review. Support Care Cancer
12.
go back to reference Driessen CM et al. (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877–881CrossRefPubMed Driessen CM et al. (2012) Assessing the impact of chemotherapy-induced peripheral neurotoxicity on the quality of life of cancer patients: the introduction of a new measure. Support Care Cancer 20(4):877–881CrossRefPubMed
13.
go back to reference Sorbe B et al. (2012) A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation. Int J Oncol 40(3):773–781PubMed Sorbe B et al. (2012) A phase II study of docetaxel weekly in combination with carboplatin every three weeks as first line chemotherapy in stage IIB-IV epithelial ovarian cancer: neurological toxicity and quality-of-life evaluation. Int J Oncol 40(3):773–781PubMed
14.
go back to reference Bhatnagar B et al. (2014) Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus 3:366CrossRefPubMedPubMedCentral Bhatnagar B et al. (2014) Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus 3:366CrossRefPubMedPubMedCentral
15.
go back to reference Speck RM et al. (2013) Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 9(5):e234–e240CrossRefPubMed Speck RM et al. (2013) Impact of chemotherapy-induced peripheral neuropathy on treatment delivery in nonmetastatic breast cancer. J Oncol Pract 9(5):e234–e240CrossRefPubMed
16.
go back to reference Dougherty PM et al. (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109(1–2):132–142CrossRefPubMed Dougherty PM et al. (2004) Taxol-induced sensory disturbance is characterized by preferential impairment of myelinated fiber function in cancer patients. Pain 109(1–2):132–142CrossRefPubMed
17.
go back to reference Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22–E28CrossRefPubMed Tofthagen C (2010) Patient perceptions associated with chemotherapy-induced peripheral neuropathy. Clin J Oncol Nurs 14(3):E22–E28CrossRefPubMed
19.
go back to reference American Cancer Society (2016) Facts and figures, A.C. Society, Editor. Atlanta American Cancer Society (2016) Facts and figures, A.C. Society, Editor. Atlanta
20.
go back to reference Bradley CJ et al. (2007) Employment and cancer: findings from a longitudinal study of breast and prostate cancer survivors. Cancer Investig 25(1):47–54CrossRef Bradley CJ et al. (2007) Employment and cancer: findings from a longitudinal study of breast and prostate cancer survivors. Cancer Investig 25(1):47–54CrossRef
21.
go back to reference Chirikos TN, Russell-Jacobs A, Jacobsen PB (2002) Functional impairment and the economic consequences of female breast cancer. Women Health 36(1):1–20CrossRefPubMed Chirikos TN, Russell-Jacobs A, Jacobsen PB (2002) Functional impairment and the economic consequences of female breast cancer. Women Health 36(1):1–20CrossRefPubMed
22.
go back to reference Forsyth PA et al. (1997) Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neuro-Oncol 35(1):47–53CrossRef Forsyth PA et al. (1997) Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neuro-Oncol 35(1):47–53CrossRef
23.
go back to reference Park, S.B., et al. (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin Park, S.B., et al. (2013) Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin
24.
go back to reference Osmani K et al. (2012) Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol 259(9):1936–1943CrossRefPubMed Osmani K et al. (2012) Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol 259(9):1936–1943CrossRefPubMed
25.
go back to reference Pignata S et al. (2006) Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in ovarian cancer (MITO-4) retrospective study. BMC Cancer 6:5CrossRefPubMedPubMedCentral Pignata S et al. (2006) Residual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in ovarian cancer (MITO-4) retrospective study. BMC Cancer 6:5CrossRefPubMedPubMedCentral
26.
go back to reference Hershman DL et al. (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774CrossRefPubMed Hershman DL et al. (2011) Association between patient reported outcomes and quantitative sensory tests for measuring long-term neurotoxicity in breast cancer survivors treated with adjuvant paclitaxel chemotherapy. Breast Cancer Res Treat 125(3):767–774CrossRefPubMed
27.
go back to reference Smith, E.M., et al. (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial, in JAMA. United States. 1359–67 Smith, E.M., et al. (2013) Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial, in JAMA. United States. 1359–67
28.
go back to reference Tanay, M.A., J. Armes, and E. Ream (2016) The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care (Engl) Tanay, M.A., J. Armes, and E. Ream (2016) The experience of chemotherapy-induced peripheral neuropathy in adult cancer patients: a qualitative thematic synthesis. Eur J Cancer Care (Engl)
29.
go back to reference Pike CT et al. (2012) Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848PubMedPubMedCentral Pike CT et al. (2012) Healthcare costs and workloss burden of patients with chemotherapy-associated peripheral neuropathy in breast, ovarian, head and neck, and nonsmall cell lung cancer. Chemother Res Pract 2012:913848PubMedPubMedCentral
30.
go back to reference Nudelman KN et al. (2014) Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLoS One 9(5):e96713CrossRefPubMedPubMedCentral Nudelman KN et al. (2014) Altered cerebral blood flow one month after systemic chemotherapy for breast cancer: a prospective study using pulsed arterial spin labeling MRI perfusion. PLoS One 9(5):e96713CrossRefPubMedPubMedCentral
31.
go back to reference Nudelman KN et al. (2016) Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol 34(7):677–683CrossRefPubMed Nudelman KN et al. (2016) Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol 34(7):677–683CrossRefPubMed
32.
go back to reference McDonald BC et al. (2013) Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun 30(Suppl):S117–S125CrossRefPubMed McDonald BC et al. (2013) Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun 30(Suppl):S117–S125CrossRefPubMed
33.
go back to reference Smith, E.M. (2013) Current methods for the assessment and management of taxane-related neuropathy, in Clin J Oncol Nurs. United States. 22–34 Smith, E.M. (2013) Current methods for the assessment and management of taxane-related neuropathy, in Clin J Oncol Nurs. United States. 22–34
34.
go back to reference Huang HQ et al. (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17(2):387–393CrossRefPubMed Huang HQ et al. (2007) Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study. Int J Gynecol Cancer 17(2):387–393CrossRefPubMed
35.
go back to reference Griffith KA et al. (2010) Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15(4):314–325CrossRefPubMed Griffith KA et al. (2010) Measures of chemotherapy-induced peripheral neuropathy: a systematic review of psychometric properties. J Peripher Nerv Syst 15(4):314–325CrossRefPubMed
36.
go back to reference Beijers A et al. (2014) Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy. J Community Support Oncol 12(11):401–406CrossRefPubMed Beijers A et al. (2014) Chemotherapy-induced peripheral neuropathy and impact on quality of life 6 months after treatment with chemotherapy. J Community Support Oncol 12(11):401–406CrossRefPubMed
37.
38.
go back to reference Calhoun EA et al. (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741–748CrossRefPubMed Calhoun EA et al. (2003) Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity (FACT/GOG-Ntx) questionnaire for patients receiving systemic chemotherapy. Int J Gynecol Cancer 13(6):741–748CrossRefPubMed
39.
go back to reference Kuroi K et al. (2009) Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer 17(8):1071–1080CrossRefPubMed Kuroi K et al. (2009) Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study). Support Care Cancer 17(8):1071–1080CrossRefPubMed
40.
go back to reference Argyriou AA et al. (2005) Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol 252(12):1459–1464CrossRefPubMed Argyriou AA et al. (2005) Paclitaxel plus carboplatin-induced peripheral neuropathy. A prospective clinical and electrophysiological study in patients suffering from solid malignancies. J Neurol 252(12):1459–1464CrossRefPubMed
41.
go back to reference Bakitas, M.A. (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy, in Nurs Res. United States. 323–31 Bakitas, M.A. (2007) Background noise: the experience of chemotherapy-induced peripheral neuropathy, in Nurs Res. United States. 323–31
42.
go back to reference Marineo G et al. (2012) Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manag 43(1):87–95CrossRef Marineo G et al. (2012) Scrambler therapy may relieve chronic neuropathic pain more effectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manag 43(1):87–95CrossRef
Metadata
Title
Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment
Authors
Noah R. Zanville
Kelly N. H. Nudelman
Dori J. Smith
Diane Von Ah
Brenna C. McDonald
Victoria L. Champion
Andrew J. Saykin
Publication date
01-11-2016
Publisher
Springer Berlin Heidelberg
Published in
Supportive Care in Cancer / Issue 11/2016
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-016-3329-5

Other articles of this Issue 11/2016

Supportive Care in Cancer 11/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine